Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

Filip Janku, MD, PhD, Ignacio Garrido-Laguna, MD, Vivianne Velez-Bravo, Gerald S. Falchook, MD, Vivek Subbiah, MD, David S. Hong, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Cesar A. Nunez, M.D., Luis E Fayad, Larry W. Kwak, MD, PhD, Elizabeth J Shpall, MD, Jennifer J. Wheler, MD, Winnie Liang, PhD, Bodour Salhia, PhD, Funda Meric-Bernstam, MD, Razelle Kurzrock, Michelle Fanale, MD

Blood (2013) 122 (21): 3048.

https://doi.org/10.1182/blood.V122.21.3048.3048

Published: 2013

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Felipe Samaniego, MD, Jillian F Wise, BS, Luis Fayad, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Vijairam Selvaraj, MD, David M. Goldenberg, ScD, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2011) 118 (21): 1796.

https://doi.org/10.1182/blood.V118.21.1796.1796

Published: 2011

Journal Articles

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Michelle Fanale, MD, William I Bensinger, MD, John C. Byrd, MD, Brett Ewald, PhD, Daniel Carreon, PhD, Johan Baeck, MD, Arnold S. Freedman, MD

Blood (2011) 118 (21): 3702.

https://doi.org/10.1182/blood.V118.21.3702.3702

Published: 2011

Journal Articles

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

Michelle Fanale, MD, Nancy L Bartlett, MD, Andres Forero-Torres, MD, Joseph Rosenblatt, MD, Sandra J Horning, MD, Anna R Franklin, MD, Carmel M Lynch, PhD, Eric L Sievers, MD, Dana A Kennedy, PharmD, BCOP

Blood (2009) 114 (22): 2731.

https://doi.org/10.1182/blood.V114.22.2731.2731

Published: 2009

Journal Articles

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD, Sattva Neelapu, MD, Michelle Fanale, MD, Maria Rodriguez, MD, Ana Ayala, RN, Barbara Pro, M.D., F.B. Hagemeister, Anas Younes, Susan Neel, Nathan Fowler, Mark Hess, Larry W. Kwak

Blood (2008) 112 (11): 3056.

https://doi.org/10.1182/blood.V112.11.3056.3056

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

Barbara Pro, MD, Luis Fayad, MD, Jorge Romaguera, MD, Michelle Fanale, MD, Anas Younes, MD, Fredrick B. Hagemeister, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, M.A. Rodriguez, MD, Larry Kwak, MD, PhD, Nam H. Dang, MD

Blood (2007) 110 (11): 3456.

https://doi.org/10.1182/blood.V110.11.3456.3456

Published: 2007

Journal Articles

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, MD, Barbara Pro, MD, Michelle Fanale, MD, Peter McLaughlin, MD, Sattva Neelapu, MD, Luis Fayad, MD, Amanda Wedgwood, RN, APN, Daniela Buglio, MD, Tracy Patterson, RN, Marja Dubay, BSc., Zuomei Li, Ph.D., Robert E. Martell, MD, Ph.D., M. Renee Ward, MD, Ph.D., R. Gregory Bociek, MD, MSc., FRCPC

Blood (2007) 110 (11): 2566.

https://doi.org/10.1182/blood.V110.11.2566.2566

Published: 2007

Journal Articles

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Maria Alma Rodriguez, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Larry Kwak, MD, Ph.D., Luis Fayad, MD, Xuelin Huang, Ph.D, Jean Bernard Durand, MD

Blood (2007) 110 (11): 4468.

https://doi.org/10.1182/blood.V110.11.4468.4468

Published: 2007

Journal Articles

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

Felipe Samaniego, MD, Luis E. Fayad, MD, Barbara Pro, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Sattva Neelapu, MD, Anas Younes, MD, Larry W. Kwak, MD

Blood (2006) 108 (11): 4722.

https://doi.org/10.1182/blood.V108.11.4722.4722

Published: 2006

NARROW

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only